ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions
ACAD Stock Forecast
ACADIA Pharmaceuticals stock forecast is as follows: an average price target of $26.57 (represents a 63.31% upside from ACAD’s last price of $16.27) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
ACAD Price Target
The average price target for ACADIA Pharmaceuticals (ACAD) is $26.57 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $62.00 to $15.00. This represents a potential 63.31% upside from ACAD's last price of $16.27.
ACAD Analyst Ratings
According to 18 Wall Street analysts, ACADIA Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ACAD stock is 0 'Strong Buy' (0.00%), 12 'Buy' (66.67%), 5 'Hold' (27.78%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).
ACADIA Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Jeffrey Hung | Morgan Stanley | $20.00 | $18.85 | 6.10% | 22.93% |
| Jun 26, 2024 | Keith Tapper | BMO Capital | $31.00 | $15.50 | 100.00% | 90.53% |
| May 09, 2024 | Andrew Fein | H.C. Wainwright | $27.00 | $17.13 | 57.62% | 65.95% |
| May 09, 2024 | Joel Beatty | Robert W. Baird | $28.00 | $17.13 | 63.46% | 72.10% |
| May 09, 2024 | Uy Ear | Mizuho Securities | $21.00 | $17.13 | 22.59% | 29.07% |
| Apr 30, 2024 | Ashwani Verma | UBS | $27.00 | $17.10 | 57.89% | 65.95% |
| Mar 12, 2024 | Ashwani Verma | UBS | $33.00 | $19.98 | 65.17% | 102.83% |
| Mar 12, 2024 | Jay Olson | Oppenheimer | $19.00 | $19.98 | -4.90% | 16.78% |
| Mar 12, 2024 | Ami Fadia | Needham | $32.00 | $19.98 | 60.16% | 96.68% |
| Mar 12, 2024 | Sumant Kulkami | Canaccord Genuity | $33.00 | $19.98 | 65.17% | 102.83% |
The latest ACADIA Pharmaceuticals stock forecast, released on Aug 07, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $20.00, which represents a 6.10% increase from the stock price at the time of the forecast ($18.85), and a 22.93% increase from ACAD last price ($16.27).
ACADIA Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 12 |
| Avg Price Target | - | $25.50 | $28.92 |
| Last Closing Price | $16.27 | $16.27 | $16.27 |
| Upside/Downside | -100.00% | 56.73% | 77.75% |
In the current month, the average price target of ACADIA Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ACADIA Pharmaceuticals's last price of $16.27. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | RBC Capital | Equal-Weight | Equal-Weight | Hold |
| Aug 07, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jun 26, 2024 | BMO Capital | Buy | Outperform | Initialise |
| Jun 25, 2024 | RBC Capital | Buy | Buy | Hold |
| May 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Apr 30, 2024 | UBS | Buy | Buy | Hold |
| Mar 25, 2024 | RBC Capital | Buy | Buy | Hold |
| Mar 12, 2024 | Oppenheimer | Perform | Perform | Hold |
| Feb 28, 2024 | Oppenheimer | Market Outperform | Market Outperform | Hold |
ACADIA Pharmaceuticals's last stock rating was published by RBC Capital on Aug 07, 2024. The company gave ACAD a "Equal-Weight" rating, the same as its previous rate.
ACADIA Pharmaceuticals Financial Forecast
ACADIA Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $211.70M | $165.24M | $118.46M | $136.49M | $130.71M | - | $115.47M | $130.76M | $131.61M | $115.22M | $106.55M | $121.01M | $120.58M | $110.10M | $90.07M | $98.33M | $94.59M | $83.20M | $62.96M | $59.57M | $58.30M |
| Avg Forecast | $263.60M | $253.70M | $248.70M | $228.95M | $255.59M | $248.66M | $235.95M | $208.31M | $223.79M | $192.32M | $166.18M | $120.06M | $134.23M | $138.76M | $130.41M | $121.91M | $135.39M | $127.93M | $124.90M | $112.01M | $122.76M | $118.82M | $103.41M | $90.75M | $96.69M | $88.49M | $72.54M | $60.93M | $65.53M | $67.63M |
| High Forecast | $270.31M | $260.16M | $255.03M | $234.78M | $262.10M | $253.00M | $241.95M | $213.62M | $228.53M | $197.21M | $170.41M | $123.12M | $137.65M | $142.30M | $130.41M | $127.72M | $141.84M | $134.02M | $130.85M | $117.34M | $128.60M | $124.48M | $108.33M | $95.07M | $101.29M | $92.70M | $75.99M | $63.83M | $78.63M | $81.16M |
| Low Forecast | $250.17M | $240.77M | $236.03M | $217.28M | $242.57M | $246.17M | $223.92M | $197.70M | $214.31M | $182.52M | $157.71M | $113.94M | $127.39M | $131.69M | $130.41M | $118.08M | $131.14M | $123.91M | $120.98M | $108.49M | $118.91M | $115.09M | $100.16M | $87.90M | $93.66M | $85.71M | $70.26M | $59.02M | $52.42M | $54.11M |
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 11 | 14 | 7 | 13 | 7 | 6 | 6 | 9 | 7 | 16 | 8 | 10 | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.10% | 0.99% | 0.99% | 1.02% | 0.94% | - | 0.95% | 0.97% | 1.03% | 0.92% | 0.95% | 0.99% | 1.01% | 1.06% | 0.99% | 1.02% | 1.07% | 1.15% | 1.03% | 0.91% | 0.86% |
ACADIA Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 14 analysts is $223.79M, with a low forecast of $214.31M, and a high forecast of $228.53M. ACAD's average Quarter revenue forecast represents a 5.71% increase compared to the company's last Quarter revenue of $211.70M (Sep 23).
ACADIA Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 11 | 14 | 7 | 13 | 7 | 6 | 6 | 9 | 7 | 16 | 8 | 10 | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-57.78M | $3.04M | $-53.58M | $-46.06M | $-30.87M | - | $-112.50M | $-42.24M | $-13.68M | $-42.34M | $-65.33M | $-64.95M | $-82.91M | $-39.20M | $-84.37M | $-48.73M | $-41.59M | $-53.88M | $-84.14M | $-64.70M | $-61.01M |
| Avg Forecast | $-118.81M | $-114.35M | $-112.09M | $-103.19M | $-115.20M | $-112.07M | $-106.34M | $-176.77M | $-100.86M | $-86.68M | $-74.90M | $-160.70M | $-60.50M | $-22.39M | $-58.78M | $-146.09M | $-36.96M | $-20.35M | $-46.57M | $-78.89M | $-71.86M | $-52.80M | $-54.35M | $-68.55M | $-51.44M | $-53.03M | $-62.26M | $-72.82M | $-70.58M | $-69.43M |
| High Forecast | $-112.75M | $-108.52M | $-106.38M | $-97.93M | $-109.33M | $-110.95M | $-100.92M | $-141.42M | $-96.59M | $-82.26M | $-71.08M | $-128.56M | $-57.42M | $-17.91M | $-58.78M | $-116.88M | $-29.57M | $-16.28M | $-37.26M | $-63.11M | $-57.49M | $-42.24M | $-43.48M | $-54.84M | $-41.15M | $-42.42M | $-49.81M | $-58.25M | $-56.46M | $-55.54M |
| Low Forecast | $-121.83M | $-117.26M | $-114.95M | $-105.82M | $-118.13M | $-114.03M | $-109.05M | $-212.13M | $-103.00M | $-88.89M | $-76.80M | $-192.85M | $-62.04M | $-26.87M | $-58.78M | $-175.31M | $-44.35M | $-24.43M | $-55.88M | $-94.67M | $-86.23M | $-63.36M | $-65.21M | $-82.26M | $-61.72M | $-63.63M | $-74.71M | $-87.38M | $-84.69M | $-83.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.67% | -0.04% | 0.33% | 0.76% | 1.38% | - | 0.77% | 1.14% | 0.67% | 0.91% | 0.83% | 0.90% | 1.57% | 0.72% | 1.23% | 0.95% | 0.78% | 0.87% | 1.16% | 0.92% | 0.88% |
7 analysts predict ACAD's average Quarter EBITDA for Sep 23 to be $-86.68M, with a high of $-82.26M and a low of $-88.89M. This is -2954.10% lower than ACADIA Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.04M.
ACADIA Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 11 | 14 | 7 | 13 | 7 | 6 | 6 | 9 | 7 | 16 | 8 | 10 | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | $-65.18M | $1.11M | $-43.02M | $-41.73M | $-27.18M | - | $-113.06M | $-43.09M | $-14.46M | $-43.87M | $-66.45M | $-66.76M | $-84.66M | $-42.14M | $-88.02M | $-53.04M | $-41.98M | $-54.94M | $-85.30M | $-65.49M | $-62.14M |
| Avg Forecast | $36.56M | $11.63M | $21.60M | $-17.45M | $18.84M | $20.85M | $29.52M | $-178.52M | $48.01M | $-74.40M | $-16.25M | $-162.29M | $-41.06M | $-23.67M | $-41.28M | $-147.54M | $-37.71M | $-21.52M | $-48.26M | $-80.24M | $-73.86M | $-53.92M | $-58.42M | $-71.52M | $-55.98M | $-53.52M | $-63.49M | $-73.82M | $-71.45M | $-70.71M |
| High Forecast | $37.77M | $12.02M | $22.32M | $-16.29M | $19.47M | $41.70M | $30.50M | $-142.82M | $88.52M | $-69.47M | $-15.18M | $-129.83M | $-38.34M | $-18.94M | $-41.28M | $-118.03M | $-30.17M | $-17.21M | $-38.61M | $-64.19M | $-59.09M | $-43.13M | $-46.74M | $-57.21M | $-44.79M | $-42.82M | $-50.79M | $-59.06M | $-57.16M | $-56.57M |
| Low Forecast | $34.14M | $10.86M | $20.17M | $-18.02M | $17.59M | $-13.27M | $27.57M | $-214.23M | $34.51M | $-76.86M | $-16.79M | $-194.75M | $-42.42M | $-28.40M | $-41.28M | $-177.05M | $-45.25M | $-25.82M | $-57.91M | $-96.29M | $-88.63M | $-64.70M | $-70.11M | $-85.82M | $-67.18M | $-64.23M | $-76.18M | $-88.58M | $-85.73M | $-84.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | -0.07% | 0.27% | 1.02% | 1.15% | - | 0.77% | 1.14% | 0.67% | 0.91% | 0.83% | 0.90% | 1.57% | 0.72% | 1.23% | 0.95% | 0.78% | 0.87% | 1.16% | 0.92% | 0.88% |
ACADIA Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-74.40M, with a range of $-76.86M to $-69.47M. ACAD's average Quarter net income forecast represents a -6778.29% decrease compared to the company's last Quarter net income of $1.11M (Jun 23).
ACADIA Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 11 | 14 | 7 | 13 | 7 | 6 | 6 | 9 | 7 | 16 | 8 | 10 | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | $97.89M | $95.97M | $101.23M | $104.40M | $78.11M | - | $96.68M | $105.91M | $81.67M | $96.79M | $111.66M | $120.75M | $81.59M | $84.34M | $101.97M | $91.87M | $72.70M | $67.98M | $93.09M | $74.27M | $61.09M |
| Avg Forecast | $206.97M | $199.19M | $195.27M | $179.76M | $200.68M | $195.23M | $185.25M | $152.66M | $175.71M | $151.00M | $130.48M | $94.27M | $105.39M | $133.71M | $102.39M | $95.72M | $92.67M | $121.56M | $106.47M | $87.94M | $96.39M | $51.96M | $81.19M | $82.85M | $75.92M | $69.48M | $56.96M | $47.84M | $51.45M | $53.10M |
| High Forecast | $212.24M | $204.26M | $200.24M | $184.34M | $205.79M | $198.64M | $189.97M | $183.19M | $179.43M | $154.84M | $133.80M | $96.67M | $108.08M | $160.45M | $102.39M | $100.28M | $111.21M | $145.87M | $127.76M | $92.13M | $100.97M | $62.35M | $85.06M | $99.42M | $79.53M | $72.78M | $59.67M | $50.12M | $61.74M | $63.72M |
| Low Forecast | $196.42M | $189.05M | $185.32M | $170.60M | $190.45M | $193.28M | $175.82M | $122.13M | $168.27M | $143.31M | $123.83M | $89.46M | $100.02M | $106.97M | $102.39M | $92.72M | $74.14M | $97.25M | $85.17M | $85.18M | $93.36M | $41.57M | $78.64M | $66.28M | $73.53M | $67.29M | $55.17M | $46.34M | $41.16M | $42.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 0.74% | 1.07% | 0.99% | 0.58% | - | 1.01% | 1.14% | 0.67% | 0.91% | 1.27% | 1.25% | 1.57% | 1.04% | 1.23% | 1.21% | 1.05% | 1.19% | 1.95% | 1.44% | 1.15% |
ACADIA Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $175.71M, based on 14 Wall Street analysts, with a range of $168.27M to $179.43M. The forecast indicates a 79.50% rise compared to ACAD last annual SG&A of $97.89M (Sep 23).
ACADIA Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 11 | 14 | 7 | 13 | 7 | 6 | 6 | 9 | 7 | 16 | 8 | 10 | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | - | $-0.70 | $-0.27 | $-0.09 | $-0.27 | $-0.42 | $-0.42 | $-0.54 | $-0.27 | $-0.57 | $-0.34 | $-0.29 | $-0.38 | $-0.59 | $-0.50 | $-0.50 |
| Avg Forecast | $0.22 | $0.07 | $0.13 | $-0.10 | $0.11 | $0.13 | $0.18 | $0.05 | $0.29 | $-0.45 | $-0.10 | $-0.21 | $-0.25 | $-0.19 | $-0.25 | $-0.62 | $-0.24 | $-0.26 | $-0.30 | $-0.53 | $-0.47 | $-0.38 | $-0.44 | $-0.48 | $-0.36 | $-0.40 | $-0.45 | $-0.52 | $-0.60 | $-0.66 |
| High Forecast | $0.23 | $0.07 | $0.13 | $-0.10 | $0.12 | $0.25 | $0.18 | $0.05 | $0.53 | $-0.42 | $-0.09 | $-0.20 | $-0.23 | $-0.18 | $-0.25 | $-0.59 | $-0.23 | $-0.25 | $-0.29 | $-0.51 | $-0.45 | $-0.37 | $-0.42 | $-0.46 | $-0.35 | $-0.39 | $-0.44 | $-0.50 | $-0.48 | $-0.53 |
| Low Forecast | $0.21 | $0.07 | $0.12 | $-0.11 | $0.11 | $-0.08 | $0.17 | $0.05 | $0.21 | $-0.46 | $-0.10 | $-0.22 | $-0.26 | $-0.20 | $-0.25 | $-0.66 | $-0.25 | $-0.28 | $-0.32 | $-0.56 | $-0.50 | $-0.41 | $-0.47 | $-0.51 | $-0.39 | $-0.43 | $-0.48 | $-0.56 | $-0.72 | $-0.79 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | -0.07% | 1.26% | 1.05% | 0.88% | - | 1.13% | 1.14% | 0.35% | 0.89% | 0.79% | 0.89% | 1.41% | 0.61% | 1.19% | 0.94% | 0.72% | 0.84% | 1.13% | 0.83% | 0.76% |
According to 7 Wall Street analysts, ACADIA Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.45, with a low estimate of $-0.46 and a high estimate of $-0.42. This represents a -6683.82% decrease compared to ACAD previous annual EPS of $0.01 (Jun 23).
ACADIA Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.70 | $70.00 | 9900.00% | Buy |
| ATHA | Athira Pharma | $0.49 | $18.00 | 3573.47% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.28 | $10.00 | 681.25% | Buy |
| CABA | Cabaletta Bio | $4.19 | $16.33 | 289.74% | Buy |
| AKRO | Akero Therapeutics | $26.64 | $46.00 | 72.67% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.26 | $26.57 | 63.41% | Buy |
| VKTX | Viking Therapeutics | $62.94 | $100.50 | 59.68% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.36 | $315.75 | 35.31% | Buy |
| SRPT | Sarepta Therapeutics | $125.69 | $169.93 | 35.20% | Buy |
| PTCT | PTC Therapeutics | $35.07 | $44.33 | 26.40% | Hold |
| BPMC | Blueprint Medicines | $86.51 | $101.50 | 17.33% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
ACAD Forecast FAQ
Is ACADIA Pharmaceuticals a good buy?
Yes, according to 18 Wall Street analysts, ACADIA Pharmaceuticals (ACAD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 66.67% of ACAD's total ratings.
What is ACAD's price target?
ACADIA Pharmaceuticals (ACAD) average price target is $26.57 with a range of $15 to $62, implying a 63.31% from its last price of $16.27. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ACADIA Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ACAD stock, the company can go up by 63.31% (from the last price of $16.27 to the average price target of $26.57), up by 281.07% based on the highest stock price target, and down by -7.81% based on the lowest stock price target.
Can ACADIA Pharmaceuticals stock reach $20?
ACAD's average twelve months analyst stock price target of $26.57 supports the claim that ACADIA Pharmaceuticals can reach $20 in the near future.
What are ACADIA Pharmaceuticals's analysts' financial forecasts?
ACADIA Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $948.51M (high $970.66M, low $910.36M), average EBITDA is $-510M (high $-463M, low $-553M), average net income is $-109M (high $-51.147M, low $-182M), average SG&A $733.83M (high $777.59M, low $681.68M), and average EPS is $0.465 (high $0.602, low $0.238). ACAD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $994.95M (high $1.02B, low $944.26M), average EBITDA is $-448M (high $-426M, low $-460M), average net income is $52.34M (high $55.81M, low $47.15M), average SG&A $781.19M (high $801.08M, low $741.39M), and average EPS is $0.315 (high $0.336, low $0.284).
Did the ACAD's actual financial results beat the analysts' financial forecasts?
Based on ACADIA Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $517.24M, which missed the average analysts forecast of $525.32M by -1.54%. Apple's EBITDA was $-224M, missing the average prediction of $-288M by -22.30%. The company's net income was $-216M, missing the average estimation of $-254M by -14.82%. Apple's SG&A was $369.09M, missing the average forecast of $437.22M by -15.58%. Lastly, the company's EPS was $-1.34, beating the average prediction of $-1.307 by 2.52%. In terms of the last quarterly report (Sep 2023), ACADIA Pharmaceuticals's revenue was $211.7M, beating the average analysts' forecast of $192.32M by 10.08%. The company's EBITDA was $-57.776M, missing the average prediction of $-86.679M by -33.34%. ACADIA Pharmaceuticals's net income was $-65.176M, missing the average estimation of $-74.396M by -12.39%. The company's SG&A was $97.89M, missing the average forecast of $151M by -35.17%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.448 by -10.65%